Cost-effectiveness of introducing a maternal vaccine or long-acting monoclonal antibody to prevent infant respiratory syncytial virus disease in Nepal
New passive immunisation strategies have the potential to prevent a substantial number of RSV-related hospitalisations and deaths in Nepal. Cost-effectiveness and product choice will heavily depend on the price negotiated for each product.
Authors
- Ram Hari Chapagain (ORCID: https://orcid.org/0000-0001-5939-5471)
- Neele Rave
- Louis Bont
- Farina L Shaaban
- Clint Pecenka (ORCID: https://orcid.org/0000-0002-2284-3557)
- Andrew Clark (ORCID: https://orcid.org/0000-0002-0272-4788)
- An Nguyen (ORCID: https://orcid.org/0000-0002-4881-7947)
- Arun K Sharma
Institutions
- Program for Appropriate Technology in Health (US)
- University Medical Center Utrecht (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Kanti Children's Hospital (NP)
- Tribhuvan University Teaching Hospital (NP)
- Mountain Medicine Society of Nepal (NP)
Publication Details
- Journal
- Journal of Global Health
- Published
- 2025-11-13
- DOI
- https://doi.org/10.7189/jogh.15.04292
- Citations
- 1
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Bill and Melinda Gates Foundation